Last reviewed · How we verify
NCT07038070
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
NA trial testing Vaginal estrogen tablet in Genitourinary Syndrome of Menopause (GSM) in 196 participants. Not yet recruiting.
1 May 2026
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 196 |
| Start date | 1 July 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Vaginal estrogen tablet — full drug profile →
- Via Solv Wellness (Hyaluronic Acid Therapy)
Conditions studied
- Genitourinary Syndrome of Menopause (GSM) — all drugs for Genitourinary Syndrome of Menopause (GSM) →
Sponsor
NYU Langone Health — full company profile →
Who can join
45 and older, female only, with Genitourinary Syndrome of Menopause (GSM). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate whether the administration of vaginal estrogen along with Via, a hyaluronic acid-based vaginal moisturizer, offers superior relief from symptoms of genitourinary syndrome of menopause (GSM) in the urogynecologic patient population, compared to administration of vaginal estrogen alone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07038070
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Genitourinary Syndrome of Menopause (GSM)
Currently open trials in the same condition.
- NCT07034976 — Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopau · NA · recruiting
- NCT06721936 — Genitourinary Syndrome of Menopause in Breast Cancer · NA · recruiting
- NCT07420647 — Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment · NA · active not recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07038070 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07038070.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing